This paper is a clinical perspective/review focused on the ongoing debate around cardiovascular (CV) safety in postmenopausal women receiving subcutaneous testosterone implant therapy. It summarizes the current state of evidence, discusses known areas of uncertainty, and frames how clinicians can think about risk assessment and monitoring when considering testosterone implants in midlife women.

We include this paper because it directly addresses one of the most common provider questions—cardiovascular safety—and synthesizes the evidence and clinical considerations relevant to testosterone implant therapy in postmenopausal women.